Advertisement

Research Article Free access | 10.1172/JCI107312

Plasma Inhibitors of the Components of the Fibrinolytic Pathway in Man

Alan D. Schreiber, Allen P. Kaplan, and K. Frank Austen

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02120

Department of Medicine Robert B. Brigham Hospital, Boston, Massachusetts 02120

Find articles by Schreiber, A. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02120

Department of Medicine Robert B. Brigham Hospital, Boston, Massachusetts 02120

Find articles by Kaplan, A. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02120

Department of Medicine Robert B. Brigham Hospital, Boston, Massachusetts 02120

Find articles by Austen, K. in: JCI | PubMed | Google Scholar

Published June 1, 1973 - More info

Published in Volume 52, Issue 6 on June 1, 1973
J Clin Invest. 1973;52(6):1394–1401. https://doi.org/10.1172/JCI107312.
© 1973 The American Society for Clinical Investigation
Published June 1, 1973 - Version history
View PDF
Abstract

The effect of highly purified inhibitor of the first component of complement (CāINH), α2 macroglobulin (α2M), and α1 antitrypsin on the components of the fibrinolytic pathway in human plasma has been examined. CāINH was the only factor active upon the Hageman factor fragments functioning at the initial step of the fibrinolytic pathway, α2M was the only factor active against the plasminogen activator and the most active inhibitor of plasmin. The inhibition of plasmin by α2M appeared stoichiometric with one molecule of α2M inhibiting two molecules of plasmin. All three plasma inhibitors were active against plasmin.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (June 1, 1973): No description
Advertisement
Advertisement